iBio, Inc.
IBIO · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $100 | $200 | $0 | $200 |
| % Growth | -50% | – | -100% | – |
| Cost of Goods Sold | $289 | $0 | $0 | $0 |
| Gross Profit | -$189 | $200 | $0 | $200 |
| % Margin | -189% | 100% | – | 100% |
| R&D Expenses | $3,550 | $3,224 | $1,906 | $1,877 |
| G&A Expenses | $2,501 | $2,174 | $2,973 | $2,742 |
| SG&A Expenses | $2,501 | $2,174 | $2,973 | $2,742 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$289 | $0 | $0 | $0 |
| Operating Expenses | $5,762 | $5,398 | $4,879 | $4,619 |
| Operating Income | -$5,951 | -$5,198 | -$4,879 | -$4,419 |
| % Margin | -5,951% | -2,599% | – | -2,209.5% |
| Other Income/Exp. Net | $231 | $35 | $18 | $55 |
| Pre-Tax Income | -$5,720 | -$5,163 | -$4,861 | -$4,364 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$5,720 | -$5,163 | -$4,861 | -$4,364 |
| % Margin | -5,720% | -2,581.5% | – | -2,182% |
| EPS | -0.11 | -0.31 | -0.49 | -0.48 |
| % Growth | 64.5% | 36.7% | -2.1% | – |
| EPS Diluted | -0.11 | -0.31 | -0.49 | -0.48 |
| Weighted Avg Shares Out | 52,981 | 16,424 | 9,862 | 9,132 |
| Weighted Avg Shares Out Dil | 52,981 | 16,424 | 9,862 | 9,132 |
| Supplemental Information | – | – | – | – |
| Interest Income | $267 | $79 | $72 | $112 |
| Interest Expense | $36 | $44 | $54 | $57 |
| Depreciation & Amortization | $289 | $285 | $282 | $281 |
| EBITDA | -$5,395 | -$4,834 | -$4,525 | -$4,026 |
| % Margin | -5,395% | -2,417% | – | -2,013% |